Publication Topic

Wikoff D, Fitch S, Vincent M, Southall MD, Atillasoy E, Weinstein RD, Ejaz SD, Rhoden JD, Choksi N. Biological plausibility assessment of acetaminophen and occurrence of developmental neurological outcomes in humans. Abstract 4768, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025. (Honored as one of the Risk Assessment Specialty Section’s Top 10 Abstracts).

Mihalchik A. Strategies to evaluate over-the-counter drug degradants. Abstract 1252, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Rogers JD, Patlewicz G, Baker E, Bettmann A, Clippinger A, Paul Friedman K. High-throughput safety pharmacology screening to better understand data-poor chemicals. Abstract 57, American Society for Cellular and Computation Toxicology 13^th Annual Meeting, Research Triangle Park, NC, October 2024.

Petrick J, Mihalchik A, Tiwary A, Kreidl L, Swartz C, Bhattarai N. Nonclinical safety evaluation of 1-monoacetin and 2-monoacetin as potential impurities in pharmaceutical excipients. Abstract 3107, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Jaeschke H, Murray FJ, Monnot AD, Jacobson-Kram D, Cohen SM, Hardisty JF, Atillasoy E… Wikoff D, et al. 2021. Assessment of the biochemical pathways for acetaminophen toxicity: Implications for its carcinogenic hazard potential. Regul Toxicol Pharmacol 120(March):104859; doi: 10.1016/j.yrtph.2020.104859. PMID: 33388367.

Ishida K, Werner J, Lafleur N, Wisler J, Wannberg S, Kalanzi J, Bussiere J, Monticello TM. 2021. Phosphatidylinositol 3-kinase δ-specific inhibitor-induced changes in the ovary and testis in the Sprague Dawley rat and cynomolgus monkey. Int J Toxicol 40(4):344-354; doi: 10.1177/109158211008175.

Winiwarter S, Ahlberg E, Watson E, Oprisiu I, Mogemark M, Noeske T, Greene N. 2018. In silico ADME in drug design–Enhancing the impact. ADMET DMPK 6(1):15-33; doi: 10.5599/admet.6.1.470.

Butler L, Guzzie-Peck P, Hartke J, Bogdanffy M, Will Y, Diaz D, Mortimer-Cassen E,.., Greene N, et al. Revised draft EMA guidance on early clinical trials: Potential impacts and industry response. Abstract P204, American College of Toxicology 2017 Annual Meeting, Palm Springs, CA, 2017. Int J Toxicol 37(1):75-76; doi: 10.1177/10915818177494, 2018.

Prior H, Bottomley A, Champeroux P, Cordes J, Delphy E, Dybdal N, et al. 2016. Social housing of non-rodents during cardiovascular recording in safety pharmacology and toxicology studies. J Pharmacol Toxicol Methods 81(Sep-Oct):75–87; doi: 10.1016/j.vascn.2016.03.004. PMID: 27039257.

Doepker C, Lieberman HR, Smith AP, Peck JD, El-Sohemy A, Welsh BT. 2016. Caffeine: Friend or foe? Annu Rev Food Sci Technol 7(Feb):117-137; doi: 10.1146/annurev-food-041715-033243.

Ulrich K. Inhalation toxicology – Regulatory aspects for pharmaceuticals. Presentation to In Vitro Toxicology Society Annual Meeting, Birmingham, UK, 2015.

Greene N, Gosink M. 2013. Computational toxicology experience and applications for risk assessment in the pharmaceutical industry. Chapter 10 in: Fowler BA (ed), Computational Toxicology: Methods and Applications. Elsevier-Academic Press, pp. 171-193; doi: 10.1016/B978-0-12-396461-8.00012-9.

Wang X, Greene N. 2012. Comparing measures of promiscuity and exploring their relationship to toxicity. Molec Inform 3(2):145-159; doi: 10.1002/minf.201100148. PMID: 27476959. Awarded Best Paper of 2012 by the editors of Molecular Informatics.

Urban JD, Clarke WP, von Zastrow M, Kobilka B, Nichols DE, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, and Mailman RB. 2007. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Therap 320(1):1-13; doi: 10.1124/jpet.106.104463.

Urban JD, Thornley K, Wightman RW, Mailman RB. Pharmacological characterization of the N27-D2L cell line: Assessment as a viable cell model for investigating D2L receptor dopaminergic-coupled functions. Society of Toxicology 46th Annual Meeting, Charlotte, NC, March 2007.

Urban JD, Mailman RB. Characterization of the N27 dopaminergic cell line as a model for elucidating the actions of functionally selective dopaminergic ligands. 35th Annual Neuroscience Meeting, Washington, DC, November 2005.

Urban JD, Gay EA, Mailman RB. Functional selectivity as a mechanism of action of newer atypical antipsychotic drugs. 34th Annual Neuroscience Meeting, San Diego, CA, October 2004.

Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE. 2004. Activation of G-proteins by morphine and codeine congeners: Insights to the relevance of O- and N-demethylated metabolites at μ- and δ-opioid receptors. J Pharmacol Exper Therapeut 308(2):547–554; doi: 10.1124/jpet.103.058602. PMID: 14600248.

Booth RG, Moniri NH, Bakker RA, Choksi NY, Nix WB, Timmerman H, Leurs R. 2002. A novel phenylaminotetralin radioligand reveals a sub-population of histamine H1 receptors. J Pharmacol Exper Therapeut 302(1):328–336; doi: 10.1124/jpet.302.1.328. PMID: 12065734.

Urban JD, Mailman RB. Functional selectivity as a mechanism of action for newer atypical antipsychotic drugs. Presented at Merck, West Point, PA, 2005.